BioCentury | Feb 11, 2019
Distillery Therapeutics

Infectious disease

...in mouse models with chronic, severe Buruli ulcers. Qurient Co. Ltd. and Infectex Ltd. have Q203...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Infectious disease

...testing the inhibitor in additional models of TB. Qurient Co. Ltd. and Infectex Ltd. have Q203...
BioCentury | Mar 21, 2016
Product Development

Korea rising

...of it," said Nam. Qurient's KDDF grants were for preclinical and clinical studies of its Q203...
...develop compounds discovered by and licensed from the Institut Pasteur Korea and other research facilities. Q203...
BioCentury | Mar 21, 2016
Finance

Multiples in Korea

...the IPO proceeds for clinical development of lead compounds Q301 to treat atopic dermatitis and Q203...
...multi-drug resistant tuberculosis. Q301 is a topical leukotriene inhibitor that has completed Phase IIa testing. Q203...
BioCentury | Feb 17, 2014
Company News

Infectex, Qurient deal

...Qurient granted Infectex exclusive rights to develop and commercialize preclinical tuberculosis compound Q203 in Russia, Armenia...
...the government of South Korea. The company has rights to the compound from the institute. Q203...
BioCentury | Aug 22, 2013
Distillery Therapeutics

Indication: Infectious disease

...replication with low nanomolar potency and were not cytotoxic to host cells. The best compound, Q203...
...lung pathology compared with vehicle in MDR M. tuberculosis-infected mice. In vitro and in mice, Q203...
BioCentury | Aug 22, 2013
Strategy

Found in translation: Institute Pasteur Korea

...institute spinout. 1 Qurient plans to start a Phase I trial of the TB compound, Q203...
...Medicine , a team led by IPK principal investigator Kevin Pethe outlined the discovery of Q203...
...activity against cultured M. tuberculosis to confirm that the compounds had a direct antimicrobial effect. Q203...
Items per page:
1 - 7 of 7